K. Flanigan

This researcher studies Duchenne muscular dystrophy (DMD), a genetic muscle-wasting disease, with a focus on developing and testing gene therapies and RNA-based treatments to restore production of dystrophin, the protein missing in DMD patients. Recent work involves clinical trials of gene therapy and exon-skipping approaches, as well as laboratory studies using engineered RNA tools to correct faulty genetic instructions in patient cells.

Publication output was minimal or absent for most of the past decade but has increased notably since 2023, with the highest activity in 2025.

Generated by claude-sonnet-5 from public bibliographic data · Jul 20, 2026